Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Generalized pustular psoriasis (GPP) is a serious and rare form of psoriasis that can cause systemic symptoms. Because GPP can be life threatening, hospitalization may be necessary when a flare ...

The following is a summary of “Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization ...

BE SURE is a phase 3, randomised, double-blind study comparing bimekizumab to Humira in adult patients with moderate-to-severe chronic plaque psoriasis. The co-primary endpoints of the study were ...

Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become ... but secondary endpoints included Psoriasis Area and Severity Index (PASI) 90, ACR 50, and physical function scores.

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment ...

Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...